IMV to Present at 2019 BIO CEO & Investor Conference
January 28 2019 - 4:35PM
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that it will participate in the BIO
CEO and Investor Conference in New York City, NY. This event will
take place February 11-12, 2019, at the New York Marriott Marquis.
Frederic Ors, IMV’s Chief Executive Officer, is
scheduled to present a corporate overview and update on Monday,
February 11, at 2:45 p.m. ET in the Herald/Soho room. His
presentation will be available on IMV’s website at www.imv-inc.com
following the meeting.
Now in its 21st year, the BIO CEO
& Investor Conference is one of the largest investor
conferences focused on established and emerging publicly traded and
select private biotech companies. Registered Investors whom are
interested meeting IMV and its management team are invited to do so
by registering online via the BIO One-on-One Partnering
TM tool.
About IMV
IMV Inc. is a clinical stage biopharmaceutical
company dedicated to making immunotherapy more effective, more
broadly applicable, and more widely available to people facing
cancer and other serious diseases. IMV is pioneering a new class of
immunotherapies based on the Company’s proprietary drug delivery
platform. This patented technology leverages a novel mechanism of
action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a
T cell-activating immunotherapy that combines the utility of the
platform with a target: survivin. IMV is currently assessing
DPX-Survivac as a monotherapy in advanced ovarian cancer, as well
as a combination therapy in multiple clinical studies with Merck.
Connect at www.imv-inc.com.
IMV Forward-Looking
Statements
This press release contains forward-looking
information under applicable securities law. All information that
addresses activities or developments that we expect to occur in the
future is forward-looking information. Forward-looking statements
are based on the estimates and opinions of management on the date
the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks
and uncertainties include, but are not limited to, our ability to
access capital, the successful and timely completion of clinical
trials, the receipt of all regulatory approvals and other risks
detailed from time to time in our ongoing quarterly filings and
annual information form. Investors are cautioned not to rely on
these forward-looking statements and are encouraged to read IMV’s
continuous disclosure documents, including its current annual
information form, as well as its audited annual consolidated
financial statements which are available on SEDAR
at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
Contacts for IMV:
MEDIA Andrea Cohen, Sam Brown
Inc.T: (917) 209-7163 E: andreaCohen@sambrown.com
INVESTOR RELATIONSMarc Jasmin, IMV
Senior Director, Investor Relations and CommunicationsO:
(902) 492-1819 M: (514) 917-9481 E: mjasmin@imv-inc.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284M: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024